Steven Marvel
Pulmonary Disease · Salem, ORNPI 1588771323
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 494 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,407 and has fallen 99.1% since, to $22 in 2024.
Across 494 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- United Therapeutics Corporation$742
- Boehringer Ingelheim$537
- Grifols USA, LLC$522
- Genentech USA, Inc.$448
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,46698%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 119 | $1,384 |
| AstraZeneca | 79 | $1,229 |
| United Therapeutics Corporation | 32 | $742 |
| Boehringer Ingelheim | 30 | $537 |
| Grifols USA, LLC | 55 | $522 |
| Genentech USA, Inc. | 25 | $448 |
| Actelion Pharmaceuticals US, Inc. | 20 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $199 |
| Mylan Specialty L.p. | 12 | $195 |
| Insmed, Inc. | 15 | $195 |
| Novartis | 11 | $174 |
| Regeneron Healthcare Solutions, Inc. | 6 | $172 |
| Electromed, Inc. | 1 | $162 |
| Sanofi | 10 | $156 |
| Philips North America LLC | 11 | $155 |
| Merck | 9 | $151 |
| Amgen | 8 | $147 |
| Gilead | 9 | $135 |
| Bayer | 7 | $113 |
| AbbVie(2 entities) | 6 | $106 |
| Shire North American Group Inc | 5 | $91 |
| Pfizer | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Harmony Biosciences LLC | 1 | $35 |
| Circassia Inc. | 2 | $27 |
| Abiomed | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $11 |
| Advanced Respiratory, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SMARTVEST$162
How this compares
$7,622 in reported general payments places this provider in the 85th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Salem
- Kamran FirooziSalem$9K
- Nimeshkumar MehtaSalem$7K
- Bijaya ShresthaSalem$4K
- Martin JohnsonSalem$4K
- Yasaman EslaamizaadSalem$3K
- Kavan RamachandranSalem$3K
- Fayez BaderSalem$2K
- James ParosaSalem$1K
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.